Chronic Inflammatory Dermatoses: Designing Trials for Late-Stage Success 

May 12th, 2026
11 a.m. EDT

Chronic, relapsing inflammatory dermatoses such as psoriasis, atopic dermatitis, vitiligo, and hidradenitis suppurativa present distinct development challenges that traditional clinical trial models were not designed to address. While therapeutic innovation has accelerated, many promising programs struggle in late-stage development, not due to lack of efficacy, but because trial designs do not fully capture durability, long-term safety, and improvements in patient experience. 

In this webinar, our experts will outline a strategic framework for designing Phase 2 and Phase 3 trials positioned for regulatory, clinical, and commercial success in chronic dermatoses. We will discuss how to move beyond short-term response rates to sustained disease control, integrate clinician and patient perspectives into endpoint strategy, design for what happens after the primary endpoint, and manage execution risks such as variability in investigator scoring and participant burden. 

For sponsors advancing dermatology assets, these strategic decisions shape not only approval and labeling outcomes, but also competitive differentiation and long-term market viability. Join us to learn how to design trials that translate early promise into sustaining value for patients and stakeholders alike. 

Attendees will gain insights into: 

• Why chronic inflammatory dermatoses require unique development strategies 
• Clinical trial design decisions that can increase the chance of late-stage success
• How to manage trial execution risk and ensure data quality  

Speaker:

Ayman Farahat, M.D. – Vice President, Medical Affairs, Global Head of Dermatology